Imbefrance SRL
Imbefrance reported total assets of €5.11m at the end of the 2025 financial year (annual accounts filed with the NBB on 25 Jul 2026).
The score of Imbefrance shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +9 % Total assets -5 %
Accounts of the company itself (not consolidated).
The full file covers 14 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Imbefrance's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 25 Jul 2026
- Year ended 31 Dec 2024filed on 17 Jun 2025
- Year ended 31 Dec 2023filed on 29 Jul 2024
- Year ended 31 Dec 2022filed on 24 Jul 2023
- Year ended 31 Dec 2021filed on 03 Aug 2022
Imbefrance's financial analysis
- Solvency81.0%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Imbefrance
Imbefrance's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0443.801.328
- VAT number
- BE0443801328
- Peppol
- Registered · 0208:0443801328 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 10 Apr 1991
- Registered office
- 1500 Halle
- Latest accounts
- 2025 · filed on 25 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Imbefrance (SRL) has been based in Halle since 1991, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 140,260 € and equity of €4.14m; its revenue is not published. Its solvency stands at 81.0%, above the median of its sector (44.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Imbefrance
Companies in the same business, of comparable size and area, outside its group.
- Apotheek Lox Retail sale of pharmaceutical products Leuven · balance sheet €5.28m
- Alpaga MDB Retail sale of pharmaceutical products Kontich · balance sheet €5.32m
- Apophar Retail sale of pharmaceutical products Ixelles · balance sheet €5.33m
- Dermatheek Retail sale of pharmaceutical products Ranst · balance sheet €5.46m
- Pharmacie Anselme Retail sale of pharmaceutical products Antoing · balance sheet €4.76m
- Pharmalliance Retail sale of pharmaceutical products Lasne · balance sheet €6.38m
- Nerum Retail sale of pharmaceutical products Heusden-Zolder · balance sheet €6.46m
- Hainapharma Retail sale of pharmaceutical products Aiseau-Presles · balance sheet €4.03m
Frequently asked questions about Imbefrance
What is the revenue of Imbefrance?
Imbefrance files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Imbefrance?
In Belgium, the VAT number is the company number prefixed with BE: BE0443801328 for Imbefrance, if the company is VAT-registered. Its company number (CBE) is 0443.801.328.
Where is the registered office of Imbefrance?
According to the CBE register, the registered office of Imbefrance is in 1500 Halle.
What is the equity of Imbefrance?
At the close of the 2025 financial year, the equity of Imbefrance amounts to 4,136,251 €, a solvency of 81.0% of total assets.
Who manages Imbefrance?
The register lists 2 active mandates at Imbefrance. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Imbefrance
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →